Publications

2020

Glutaredoxin 1 Downregulation in the Substantia Nigra Leads to Dopaminergic Degeneration in Mice

A. Verma; A. Ray; D. Bapat; L. Diwakar; R. P. Kommaddi et al. 

Movement Disorders. 2020-07-03. DOI : 10.1002/mds.28190.

2019

Glutaredoxin1 Diminishes Amyloid Beta-Mediated Oxidation of F-Actin and Reverses Cognitive Deficits in an Alzheimer’s Disease Mouse Model

R. P. Kommaddi; D. S. Tomar; S. Karunakaran; D. Bapat; S. Nanguneri et al. 

Antioxidants & Redox Signaling. 2019-12-20. Vol. 31, num. 18, p. 1321-1338. DOI : 10.1089/ars.2019.7754.

Allele-specific gene disruption through discrimination of a single base change by S. aureus Cas9-KKH prevents progressive hearing loss after AAV-mediated gene delivery

B. Gyorgy; C. Nist-Lund; B. Pan; Y. Asai; K. D. Karavitaki et al. 

2019-11-01. ESGCT 27th Annual Congress in collaboration with SETGyc Meeting, Barcelona, SPAIN, Oct 22-25, 2019. p. A11-A12.

Delivery of CRISPR/Cas9 using AAV-PHP.B in the inner ear leads to allele-specific inactivation of the mutated Tmc1 allele and protects auditory function in Beethoven mice

P. Solanes; S. Spataro; Y. Asai; B. Pan; C. A. Nist-Lund et al. 

2019-11-01. ESGCT 27th Annual Congress in collaboration with SETGyc Meeting, Barcelona, SPAIN, Oct 22-25, 2019. p. A106-A107.

Allele-specific gene editing prevents deafness in a model of dominant progressive hearing loss

B. Gyorgy; C. Nist-Lund; B. Pan; Y. Asai; K. D. Karavitaki et al. 

Nature Medicine. 2019-07-01. Vol. 25, num. 7, p. 1123-+. DOI : 10.1038/s41591-019-0500-9.

Evolution of the neurochemical profiles in the G93A-SOD1 mouse model of amyotrophic lateral sclerosis

H. Lei; E. A. Dirren; C. Poitry-Yamate; B. Schneider; R. Gruetter et al. 

Journal of Cerebral Blood Flow and Metabolism. 2019-07-01. Vol. 39, num. 7, p. 1283–1298. DOI : 10.1177/0271678X18756499.

Scalable Production of AAV Vectors in Orbitally Shaken HEK293 Cells

D. Blessing; G. Vachey; C. Pythoud; M. Rey; V. Padrun et al. 

Molecular Therapy-Methods & Clinical Development. 2019-06-14. Vol. 13, p. 14-26. DOI : 10.1016/j.omtm.2018.11.004.

The RNA-Binding Protein PUM2 Impairs Mitochondrial Dynamics and Mitophagy During Aging

D. D’Amico; A. Mottis; F. Potenza; V. Sorrentino; H. Li et al. 

Molecular Cell. 2019-02-21. Vol. 73, num. 4, p. 775-+. DOI : 10.1016/j.molcel.2018.11.034.

Altered interplay between endoplasmic reticulum and mitochondria in Charcot-Marie-Tooth type 2A neuropathy

N. Bernard-Marissal; G. van Hameren; M. Juneja; C. Pellegrino; L. Louhivuori et al. 

Proceedings Of The National Academy Of Sciences Of The United States Of America. 2019-02-05. Vol. 116, num. 6, p. 2328-2337. DOI : 10.1073/pnas.1810932116.

Compositions and methods for delivering nucleic acids to cochlear and vestibular cells

J. R. Holt; Y. Asai; P. A. Solanes Vega; B. Schneider 

WO2019173367.

2019.

2018

Cas9/gRNA selective targeting of the Beethoven tmc-1 mutant allele for treating progressive hearing loss by AAV-based delivery

P. Solanes; Y. Asai; B. Pan; C. A. Nist-Lund; P. Aebischer et al. 

2018-12-01. Conference on Changing the Face of Modern Medicine – Stem Cell and Gene Therapy, Lausanne, SWITZERLAND, Oct 16-19, 2018. p. A107-A108.

An miRNA-based gene therapy approach to target mutated SOD1 in key cell types in amyotrophic lateral sclerosis (ALS)

V. Vilmont; J. Aebischer; C. Rochat; B. L. Schneider 

2018-12-01. Conference on Changing the Face of Modern Medicine – Stem Cell and Gene Therapy, Lausanne, SWITZERLAND, Oct 16-19, 2018. p. A80-A80.

Pathogenic commonalities between spinal muscular atrophy and amyotrophic lateral sclerosis: Converging roads to therapeutic development

M. Bowerman; L. M. Murray; F. Scamps; B. L. Schneider; R. Kothary et al. 

European Journal Of Medical Genetics. 2018-11-01. Vol. 61, num. 11, p. 685-698. DOI : 10.1016/j.ejmg.2017.12.001.

Cas9/gRNAs Selective Targeting of the Beethoven Tmc-1 Mutant Allele for Treating Progressive Hearing Loss by AAV-Based Delivery

P. Solanes; B. Pan; P. Aebischer; J. R. Holt; B. Schneider 

2018-05-01. 21st Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT), Chicago, IL, May 16-19, 2018. p. 138-139.

Encapsulation device

A. Lathuilière; N. Bouche; B. Schneider 

JP6417023; JP2018083819.

2018.

PFN2 and GAMT as common molecular determinants of axonal Charcot-Marie-Tooth disease

M. Juneja; A. Azmi; J. Baets; A. Roos; M. Jennings et al. 

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 2018. Vol. 89, num. 8, p. 870-878. DOI : 10.1136/jnnp-2017-317562.

Exogenous LRRK2(G2019S) induces parkinsonian-like pathology in a nonhuman primate

N. Mestre-Frances; N. Serratrice; A. Gennetier; G. Devau; S. Cobo et al. 

JCI INSIGHT. 2018. Vol. 3, num. 14, p. e98202. DOI : 10.1172/jci.insight.98202.

Endoplasmic reticulum and mitochondria in diseases of motor and sensory neurons: a broken relationship?

N. Bernard-Marissal; R. Chrast; B. Schneider 

CELL DEATH AND DISEASE. 2018. Vol. 9. DOI : 10.1038/s41419-017-0125-1.

Cortico–reticulo–spinal circuit reorganization enables functional recovery after severe spinal cord contusion

L. Asboth; L. Friedli; J. Beauparlant; C. Martinez-Gonzalez; S. Anil et al. 

Nature Neuroscience. 2018. Vol. 21, num. 4, p. 576-588. DOI : 10.1038/s41593-018-0093-5.

PM20D1 is a quantitative trait locus associated with Alzheimer’s disease

J. V. Sanchez-Mut; H. Heyn; B. A. Silva; L. Dixsaut; P. Garcia-Esparcia et al. 

Nature Medicine. 2018. Vol. 24, num. 5, p. 598-603. DOI : 10.1038/s41591-018-0013-y.

G2019S LRRK2 enhances the neuronal transmission of tau in the mouse brain

A. P. T. Nguyen; G. Daniel; P. Valdés; M. S. Islam; B. L. Schneider et al. 

2018-01-01.  p. 120-134. DOI : 10.1093/hmg/ddx389.

2017

In vivo neurochemical measurements in cerebral tissues using a droplet-based monitoring system

G. Petit-Pierre; P. Colin; E. Laurer; J. Déglon; A. Bertsch et al. 

Nature Communications. 2017. Vol. 8, num. 1, p. 1239. DOI : 10.1038/s41467-017-01419-1.

Validation of Scalable and Compliant AAV Production

D. R. Blessing; G. Vachey; B. Schneider; F. M. Wurm; N. Deglon 

2017. 20th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT), Washington, DC, MAY 10-13, 2017. p. 326-326.

Bicistronic aav vector for rna interference in als

J. Aebischer; B. Schneider; C. Rochat 

US2018228919; EP3325632; WO2017013252; EP3121284.

2017.

Parkin functionally interacts with PGC-1 proportional to to preserve mitochondria and protect dopaminergic neurons

L. Zheng; N. Bernard-Marissal; N. Moullan; D. D’Amico; J. Auwerx et al. 

Human Molecular Genetics. 2017. Vol. 26, num. 3, p. 582-598. DOI : 10.1093/hmg/ddw418.

2016

Amyloid-beta plaque deposition measured using propagation-based X-ray phase contrast CT imaging

A. Astolfo; A. Lathuiliere; V. Laversenne; B. Schneider; M. Stampanoni 

Journal of Synchrotron Radiation. 2016-04-16. Vol. 23, p. 813-819. DOI : 10.1107/S1600577516004045.

Encapsulation device

A. Lathuiliere; N. Bouche; B. Schneider 

EP2988699; CN105142570; JP6325649; US9950149; US2016184569; JP2016516827; EP2988699; CN105142570; WO2014173441.

2016.

Characterization Of Motor And Sensory Neuronal Dysfunction In Both In Vitro And In Vivo Models Of Cmt2A Pathology

N. Bernard-Marissal; C. Rochat; J. J. Medard; B. L. Schneider; R. Chrast 

2016. Inflammatory Neuropathy Consortium and GBS 100 Centenary Symposium and Ceilidh, Univ Glasgow, Glasgow, SCOTLAND, JUN 21-24, 2016. p. 239-240.

In Vivo Evidence for a Lactate Gradient from Astrocytes to Neurons

P. Machler; M. T. Wyss; M. Elsayed; J. Stobart; R. Gutierrez et al. 

Cell Metabolism. 2016. Vol. 23, num. 1, p. 94-102. DOI : 10.1016/j.cmet.2015.10.010.

Use of a Bicistronic Vector to Silence SOD1 in Motoneurons and Astrocytes for the Treatment of Familial Amyotrophic Lateral Sclerosis

J. Bobela-Aebischer; C. Rochat; N. Bernard-Marissal; P. Aebischer; B. L. Schneider 

2016. 19th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT), Washington, DC, MAY 04-07, 2016. p. S240-S240.

Suspension-Adapted HEK 293 Cells in Orbital Shaken Bioreactors for the Production of Adeno-Associated Virus Vectors

D. R. Blessing; B. Schneider; F. M. Wurm; N. Deglon 

2016. 19th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT), Washington DC, USA, May 4-7, 2016. p. S183-S184.

A subcutaneous cellular implant for passive immunization against amyloid-beta reduces brain amyloid and tau pathologies

A. Lathuiliere; V. Laversenne; A. Astolfo; E. Kopetzki; H. Jacobsen et al. 

Brain. 2016. Vol. 139, p. 1587-1604. DOI : 10.1093/brain/aww036.

Regulation of Memory Formation by the Transcription Factor XBP1

G. Martinez; R. L. Vidal; P. Mardones; F. G. Serrano; A. O. Ardiles et al. 

Cell Reports. 2016. Vol. 14, num. 6, p. 1382-1394. DOI : 10.1016/j.celrep.2016.01.028.

2015

Alpha-Synuclein as a Mediator in the Interplay between Aging and Parkinson’s Disease

W. Bobela; P. Aebischer; B. L. Schneider 

Biomolecules. 2015. Vol. 5, num. 4, p. 2675-2700. DOI : 10.3390/biom5042675.

SOD1 silencing in motoneurons or glia rescues neuromuscular function in ALS mice

E. Dirren; J. Aebischer; C. Rochat; C. Towne; B. L. Schneider et al. 

Annals Of Clinical And Translational Neurology. 2015. Vol. 2, num. 2, p. 167-184. DOI : 10.1002/acn3.162.

Chondroitinase gene therapy improves upper limb function following cervical contusion injury

N. D. James; J. Shea; E. M. Muir; J. Verhaagen; B. L. Schneider et al. 

Experimental Neurology. 2015. Vol. 271, p. 131-135. DOI : 10.1016/j.expneurol.2015.05.022.

PGC-1 alpha activity in nigral dopamine neurons determines vulnerability to alpha-synuclein

C. Ciron; L. Zheng; W. Bobela; G. W. Knott; T. C. Leone et al. 

Acta Neuropathologica Communications. 2015. Vol. 3, p. 16. DOI : 10.1186/s40478-015-0200-8.

Encapsulated Cellular Implants for Recombinant Protein Delivery and Therapeutic Modulation of the Immune System

A. Lathuiliere; N. Mach; B. L. Schneider 

International Journal Of Molecular Sciences. 2015. Vol. 16, num. 5, p. 10578-10600. DOI : 10.3390/ijms160510578.

Transient Production of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Therapy Applications Using Suspension-Adapted HEK 293 Cells in Orbital Shaken Bioreactors

D. R. Blessing; M. Montavon; M. De Jesus; L. Baldi; B. Schneider et al. 

2015. 18th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT)’. p. S184-S185.

Tmc gene therapy restores auditory function in deaf mice

C. Askew; C. Rochat; B. Pan; Y. Asai; H. Ahmed et al. 

Science Translational Medicine. 2015. Vol. 7, num. 295. DOI : 10.1126/scitranslmed.aab1996.

Pathway-specific reorganization of projection neurons in somatosensory cortex during learning

J. L. Chen; D. J. Margolis; A. Stankov; L. T. Sumanovski; B. L. Schneider et al. 

Nature Neuroscience. 2015. Vol. 18, num. 8, p. 1101-+. DOI : 10.1038/nn.4046.

Marinesco-Sjogren syndrome protein SIL1 regulates motor neuron subtype-selective ER stress in ALS

A. F. De L’Etang; N. Maharjan; M. C. Brana; C. Ruegsegger; R. Rehmann et al. 

Nature Neuroscience. 2015. Vol. 18, num. 2, p. 227-238. DOI : 10.1038/nn.3903.

Channel-Mediated Lactate Release by K+-Stimulated Astrocytes

T. Sotelo-Hitschfeld; M. I. Niemeyer; P. Maechler; I. Ruminot; R. Lerchundi et al. 

Journal Of Neuroscience. 2015. Vol. 35, num. 10, p. 4168-4178. DOI : 10.1523/Jneurosci.5036-14.2015.

alpha-Synuclein-induced dopaminergic neurodegeneration in a rat model of Parkinson’s disease occurs independent of ATP13A2 (PARK9)

G. Daniel; A. Musso; E. Tsika; A. Fiser; L. Glauser et al. 

Neurobiology Of Disease. 2015. Vol. 73, p. 229-243. DOI : 10.1016/j.nbd.2014.10.007.

Perineuronal net digestion with chondroitinase restores memory in mice with tau pathology

S. Yang; M. Cacquevel; L. M. Saksida; T. J. Bussey; B. L. Schneider et al. 

Experimental neurology. 2015. Vol. 265C, p. 48-58. DOI : 10.1016/j.expneurol.2014.11.013.

The adipocyte differentiation protein APMAP is an endogenous suppressor of Aβ production in the brain

S. Mosser; J-R. Alattia; M. Dimitrov; A. Matz; J. Pascual et al. 

Human Molecular Genetics. 2015. Vol. 24, num. 2, p. 371-382. DOI : 10.1093/hmg/ddu449.

2014

Loss of MITF expression during human embryonic stem cell differentiation disrupts retinal pigment epithelium development and optic vesicle cell proliferation

E. E. Capowski; J. M. Simonett; E. M. Clark; L. S. Wright; S. E. Howden et al. 

Human Molecular Genetics. 2014. Vol. 23, num. 23, p. 6332-6344. DOI : 10.1093/hmg/ddu351.

A Parkinson’s disease gene regulatory network identifies the signaling protein RGS2 as a modulator of LRRK2 activity and neuronal toxicity

J. Dusonchet; H. Li; M. Guillily; M. Liu; K. Stafa et al. 

Human Molecular Genetics. 2014. Vol. 23, num. 18, p. 4887-4905. DOI : 10.1093/hmg/ddu202.

Parkinson’s disease-linked mutations in VPS35 induce dopaminergic neurodegeneration

E. Tsika; L. Glauser; R. Moser; A. Fiser; G. Daniel et al. 

Human Molecular Genetics. 2014. Vol. 23, num. 17, p. 4621-4638. DOI : 10.1093/hmg/ddu178.

Control of dopaminergic neuron survival by the unfolded protein response transcription factor XBP1

P. Valdes; G. Mercado; R. L. Vidal; C. Molina; G. Parsons et al. 

Proceedings Of The National Academy Of Sciences Of The United States Of America. 2014. Vol. 111, num. 18, p. 6804-6809. DOI : 10.1073/pnas.1321845111.

Large-Scale Chondroitin Sulfate Proteoglycan Digestion with Chondroitinase Gene Therapy Leads to Reduced Pathology and Modulates Macrophage Phenotype following Spinal Cord Contusion Injury

K. Bartus; N. D. James; A. Didangelos; K. D. Bosch; J. Verhaagen et al. 

Journal Of Neuroscience. 2014. Vol. 34, num. 14, p. 4822-4836. DOI : 10.1523/Jneurosci.4369-13.2014.

FOXO3 determines the accumulation of alpha-synuclein and controls the fate of dopaminergic neurons in the substantia nigra

E. Pino; R. Amamoto; L. Zheng; M. Cacquevel; J-C. Sarria et al. 

Human Molecular Genetics. 2014. Vol. 23, num. 6, p. 1435-1452. DOI : 10.1093/hmg/ddt530.

Intracerebroventricular Injection of Adeno-Associated Virus 6 and 9 Vectors for Cell Type-Specific Transgene Expression in the Spinal Cord

E. Dirren; C. L. Towne; V. Setola; D. E. J. Redmond; B. L. Schneider et al. 

Human Gene Therapy. 2014. Vol. 25, num. 2, p. 109-120. DOI : 10.1089/hum.2013.021.

Genetic engineering of cell lines using lentiviral vectors to achieve antibody secretion following encapsulated implantation

A. Lathuiliere; B. Bohrmann; E. Kopetzki; C. Schweitzer; H. Jacobsen et al. 

Biomaterials. 2014. Vol. 35, num. 2, p. 792-802. DOI : 10.1016/j.biomaterials.2013.10.026.

A high-capacity cell macroencapsulation system supporting the long-term survival of genetically engineered allogeneic cells

A. Lathuilière; S. Cosson; M. Lütolf; B. Schneider; P. Aebischer 

Biomaterials. 2014. Vol. 35, num. 2, p. 779-791. DOI : 10.1016/j.biomaterials.2013.09.071.

2013

Measurement of autophagy flux in the nervous system in vivo

K. Castillo; V. Valenzuela; S. Matus; M. Nassif; M. Onate et al. 

Cell Death & Disease. 2013. Vol. 4. DOI : 10.1038/cddis.2013.421.

Dysregulation of voltage-gated sodium channels by ubiquitin ligase NEDD4-2 in neuropathic pain

C. J. Laedermann; M. Cachemaille; G. Kirschmann; M. Pertin; R-D. Gosselin et al. 

Journal Of Clinical Investigation. 2013. Vol. 123, num. 7, p. 3002-3013. DOI : 10.1172/Jci68996.

Behaviour-dependent recruitment of long-range projection neurons in somatosensory cortex

J. L. Chen; S. Carta; J. Soldado-Magraner; B. L. Schneider; F. Helmchen 

Nature. 2013. Vol. 499, num. 7458, p. 336-+. DOI : 10.1038/nature12236.

Overexpression of parkin in the rat nigrostriatal dopamine system protects against methamphetamine neurotoxicity

B. Liu; R. Traini; B. Killinger; B. L. Schneider; A. Moszczynska 

Experimental Neurology. 2013. Vol. 247, p. 359-372. DOI : 10.1016/j.expneurol.2013.01.001.

Direct and Retrograde Transduction of Nigral Neurons with AAV6, 8, and 9 and Intraneuronal Persistence of Viral Particles

K. Loew; P. Aebischer; B. L. Schneider 

Human Gene Therapy. 2013. Vol. 24, num. 6, p. 613-629. DOI : 10.1089/hum.2012.174.

Polo-like kinase 2 regulates selective autophagic α-synuclein clearance and suppresses its toxicity in vivo

A. Oueslati; B. L. Schneider; P. Aebischer; H. A. Lashuel 

Proceedings of the National Academy of Sciences of the United States of America. 2013. Vol. 110, num. 41, p. E3945-54. DOI : 10.1073/pnas.1309991110.

Focal expression of adeno-associated viral-mutant tau induces widespread impairment in an APP mouse model

E. Dassie; M. R. Andrews; J-C. Bensadoun; M. Cacquevel; B. L. Schneider et al. 

Neurobiology Of Aging. 2013. Vol. 34, num. 5, p. 1355-1368. DOI : 10.1016/j.neurobiolaging.2012.11.011.

An in vivo ultrahigh field 14.1 T (1) H-MRS study on 6-OHDA and α-synuclein-based rat models of Parkinson’s disease: GABA as an early disease marker

P. Coune; M. Craveiro; M. Gaugler; V. Mlynárik; B. Schneider et al. 

NMR in biomedicine. 2013. Vol. 26, num. 1, p. 43-50. DOI : 10.1002/nbm.2817.

2012

Parkinson’s Disease: Gene Therapies

P. G. Coune; B. L. Schneider; P. Aebischer 

Cold Spring Harbor Perspectives In Medicine. 2012. Vol. 2, num. 4. DOI : 10.1101/cshperspect.a009431.

Proton and phosphorus magnetic resonance spectroscopy of a mouse model of Alzheimer’s disease

V. Mlynárik; M. Cacquevel; L. Sun-Reimer; S. Janssens; C. Cudalbu et al. 

Journal of Alzheimer’s disease : JAD. 2012. Vol. 31, p. S87-99. DOI : 10.3233/JAD-2012-112072.

Nigrostriatal overabundance of alpha-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity

M. N. Gaugler; O. Genc; W. Bobela; S. Mohanna; M. T. Ardah et al. 

Acta Neuropathologica. 2012. Vol. 123, num. 5, p. 653-669. DOI : 10.1007/s00401-012-0963-y.

Endoplasmic Reticulum Stress Is Important for the Manifestations of alpha-Synucleinopathy In Vivo

E. Colla; P. Coune; Y. Liu; O. Pletnikova; J. C. Troncoso et al. 

Journal Of Neuroscience. 2012. Vol. 32, p. 3306-3320. DOI : 10.1523/JNEUROSCI.5367-11.2012.

α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer

B. Fauvet; M. K. Mbefo; M-B. Fares; C. Desobry; S. Michael et al. 

The Journal of biological chemistry. 2012. Vol. 287, num. 19, p. 15345-64. DOI : 10.1074/jbc.M111.318949.

Mimicking Phosphorylation at Serine 87 Inhibits the Aggregation of Human α-Synuclein and Protects against Its Toxicity in a Rat Model of Parkinson’s Disease

A. Oueslati; K. E. Paleologou; B. L. Schneider; P. Aebischer; H. A. Lashuel 

The Journal of neuroscience : the official journal of the Society for Neuroscience. 2012. Vol. 32, num. 5, p. 1536-44. DOI : 10.1523/JNEUROSCI.3784-11.2012.

Sustained expression of PGC-1α in the rat nigrostriatal system selectively impairs dopaminergic function

C. Ciron; S. Lengacher; J. Dusonchet; P. Aebischer; B. Schneider 

Human Molecular Genetics. 2012. Vol. 21, num. 8, p. 1861-1876. DOI : 10.1093/hmg/ddr618.

2011

Proton and phosphorus MRS of a 5xFAD mouse model of Alzheimer’s disease

V. Mlynarik; L. Sun-Reimer; S. Janssens; M. Cacquevel; H. Lei et al. 

2011. ISMRM 19th Annual Meeting & Exhibition, Montreal, Canada, May 7-13, 2011.

Early metabolic changes in the amyotrophic lateral sclerosis SOD1 mouse brain are revealed using 1H MRS rather than CASL and 18FDG PET

H. Lei; E. Dirren; C. Poitry-Yamate; B. Schneider; P. Aebischer et al. 

2011. 19th Scientific Meeting of the International Society for Magnetic Resonance in Medicine, 2011, Montréal, Québec, Canada,

Rab1A Over-Expression Prevents Golgi Apparatus Fragmentation and Partially Corrects Motor Deficits in an Alpha-Synuclein Based Rat Model of Parkinson’s Disease

P. G. Coune; J-C. Bensadoun; P. Aebischer; B. Schneider 

Journal of Parkinson’s Disease. 2011. Vol. 1, p. 373-387. DOI : 10.3233/JPD-2011-11058.

Lentiviral vectors express chondroitinase ABC in cortical projections and promote sprouting of injured corticospinal axons

R-R. Zhao; E. M. Muir; J. N. Alves; H. Rickman; A. Y. Allan et al. 

Journal Of Neuroscience Methods. 2011. Vol. 201, num. 1, p. 228-238. DOI : 10.1016/j.jneumeth.2011.08.003.

A Rat Model of Progressive Nigral Neurodegeneration Induced by the Parkinson’s Disease-Associated G2019S Mutation in LRRK2

J. Dusonchet; O. Kochubey; K. Stafa; S. M. Young; R. Zufferey et al. 

Journal of Neuroscience. 2011. Vol. 31, num. 3, p. 907-912. DOI : 10.1523/JNEUROSCI.5092-10.2011.

2010

Alpha-Synuclein Animal Models

M. Gaugler; P. G. Coune; S. Mohana; O. Genc; O. El-Agnaf et al. 

2010. 2nd World Parkinson Congress, Glasgow, UK, September 28 – October 1, 2010. p. S606-S606.

Effective Delivery of the Neuroprotectant to the Brain

P. Aebischer; E. Pino; M. Cacquevel; B. Schneider 

2010. 2nd World Parkinson Congress, Glasgow, UK, September 28 – October 1, 2010. p. S602-S602.

Neuroprotection by Gene Therapy Targeting Mutant SOD1 in Individual Pools of Motor Neurons Does not Translate Into Therapeutic Benefit in fALS Mice

C. Towne; V. Setola; B. L. Schneider; P. Aebischer 

Molecular therapy : the journal of the American Society of Gene Therapy. 2010. Vol. 19, num. 2, p. 274-83. DOI : 10.1038/mt.2010.260.

Long-range connectivity of mouse primary somatosensory barrel cortex

R. Aronoff; F. Matyas; C. Mateo; C. Ciron; B. Schneider et al. 

The European journal of neuroscience. 2010. Vol. 31, num. 12, p. 2221-33. DOI : 10.1111/j.1460-9568.2010.07264.x.

Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6

C. Towne; B. Schneider; D. Kieran; D. Redmond; P. Aebischer 

Gene Therapy. 2010. Vol. 17, num. 1, p. 141-146. DOI : 10.1038/gt.2009.119.

Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions

K. E. Paleologou; A. Oueslati; G. Shakked; C. C. Rospigliosi; H-Y. Kim et al. 

The Journal of neuroscience : the official journal of the Society for Neuroscience. 2010. Vol. 30, num. 9, p. 3184-98. DOI : 10.1523/JNEUROSCI.5922-09.2010.

2009

Targeted overexpression of the parkin substrate Pael-R in the nigrostriatal system of adult rats to model Parkinson’s disease

J. Dusonchet; J. Bensadoun; B. Schneider; P. Aebischer 

Neurobiology of disease. 2009. Vol. 35, num. 1, p. 32-41. DOI : 10.1016/j.nbd.2009.03.013.

Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson’s disease

S. Azeredo da Silveira; B. Schneider; C. Cifuentes-Diaz; D. Sage; T. Abbas-Terki et al. 

Human Molecular Genetics. 2009. Vol. 18, num. 5, p. 872-887. DOI : 10.1093/hmg/ddn417.

2008

Regulation of Prenatal Human Retinal Neurosphere Growth and Cell Fate Potential by Retinal Pigment Epithelium and Mash1

D. M. Gamm; L. S. Wright; E. E. Capowski; R. L. Shearer; J. S. Meyer et al. 

Stem Cells. 2008. Vol. 26, p. 3182-3193. DOI : 10.1634/stemcells.2008-0300.

Viral vectors: a potent approach to generate genetic models of Parkinson’s disease

B. Schneider; M. Gaugler; P. Aebischer 

Parkinson’s disease: Molecular and therapeutics insights from model systems; New York: Academic Press, 2008. p. 269-281.

Viral vectors, animal models and new therapies for Parkinson’s disease

B. Schneider; R. Zufferey; P. Aebischer 

Parkinsonism Realted Disorders. 2008. Vol. 14, num. Suppl 2, p. S169-S171. DOI : 10.1016/j.parkreldis.2008.04.024.

Systemic AAV6 delivery mediating RNA interference against SOD1: neuromuscular transduction does not alter disease progression in fALS mice

C. Towne; C. Raoul; B. L. Schneider; P. Aebischer 

Molecular Therapy. 2008. Vol. 16, num. 6, p. 1018-25. DOI : 10.1038/mt.2008.73.

2007

Over-expression of alpha-synuclein in human neural progenitors leads to specific changes in fate and differentiation

B. L. Schneider; C. R. Seehus; E. E. Capowski; P. Aebischer; S. C. Zhang et al. 

Human Molecular Genetics. 2007. Vol. 16, num. 6, p. 651-66. DOI : 10.1093/hmg/ddm008.

Lentiviral vector-mediated genetic modification of human neural progenitor cells for ex vivo gene therapy

E. E. Capowski; B. L. Schneider; A. D. Ebert; C. R. Seehus; J. Szulc et al. 

Journal of Neuroscience Methods. 2007. Vol. 163, num. 2, p. 338-49. DOI : 10.1016/j.jneumeth.2007.02.022.

2006

Transient striatal delivery of GDNF via encapsulated cells leads to sustained behavioral improvement in a bilateral model of Parkinson disease

A. Sajadi; J. Bensadoun; B. Schneider; C. Lo Bianco; P. Aebischer 

Neurobiol Dis. 2006. Vol. 22, num. 1, p. 119-29. DOI : 10.1016/j.nbd.2005.10.006.

Inducing tolerance to a soluble foreign antigen by encapsulated cell transplants

W. E. Blanco-Bose; B. L. Schneider; P. Aebischer 

Molecular Therapy. 2006. Vol. 13, num. 2, p. 447-56. DOI : 10.1016/j.ymthe.2005.08.010.

Human neural progenitors deliver glial cell line-derived neurotrophic factor to parkinsonian rodents and aged primates

S. Behrstock; A. Ebert; J. McHugh; S. Vosberg; J. Moore et al. 

Gene Therapy. 2006. Vol. 13, num. 5, p. 379-88. DOI : 10.1038/sj.gt.3302679.

2004

Wlds-mediated protection of dopaminergic fibers in an animal model of Parkinson disease

A. Sajadi; B. L. Schneider; P. Aebischer 

Current Biology. 2004. Vol. 14, num. 4, p. 326-30. DOI : 10.1016/S0960-9822(04)00050-8.

Survival of encapsulated human primary fibroblasts and erythropoietin expression under xenogeneic conditions

F. Schwenter; B. L. Schneider; W. F. Pralong; N. Deglon; P. Aebischer 

Human Gene Therapy. 2004. Vol. 15, num. 7, p. 669-80. DOI : 10.1089/1043034041361172.

Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson’s disease

C. Lo Bianco; B. L. Schneider; M. Bauer; A. Sajadi; A. Brice et al. 

Proceedings Of The National Academy Of Sciences Of The United States Of America. 2004. Vol. 101, num. 50, p. 17510-5. DOI : 10.1073/pnas.0405313101.

Using human neural stem cells to model neurological disease

R. J. Jakel; B. L. Schneider; C. N. Svendsen 

Nat Rev Genet. 2004. Vol. 5, num. 2, p. 136-44. DOI : 10.1038/nrg1268.

2003

Cellular implants: pioneers in xenotransplantation?

B. L. Schneider; P. Aebischer 

Xenotransplantation. 2003. Vol. 10, num. 2, p. 96-97. DOI : 10.1034/j.1399-3089.2003.02086.x.

Prevention of the initial host immuno-inflammatory response determines the long-term survival of encapsulated myoblasts genetically engineered for erythropoietin delivery

B. L. Schneider; F. Schwenter; W. F. Pralong; P. Aebischer 

Molecular Therapy. 2003. Vol. 7, num. 4, p. 506-14. DOI : 10.1016/S1525-0016(03)00055-8.

2002

Encapsulation as a strategy for cell xenotransplantation

B. Schneider; P. Aebischer 

Future strategies for tissue and organ replacement; London: Imperial College Press, 2002. p. 291-322.

Long-term doxycycline-regulated secretion of erythropoietin by encapsulated myoblasts

B. Sommer; C. Rinsch; E. Payen; B. Dalle; B. Schneider et al. 

Molecular Therapy. 2002. Vol. 6, num. 2, p. 155-61. DOI : 10.1006/mthe.2002.0646.